Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015 (2015), Article ID 424019, 8 pages
http://dx.doi.org/10.1155/2015/424019
Review Article

TNF-Related Apoptosis Inducing Ligand in Ocular Cancers and Ocular Diabetic Complications

1Department of Biomedical and Specialist Surgical Sciences, University of Ferrara, 44121 Ferrara, Italy
2Institute for Maternal and Child Health-IRCCS “Burlo Garofolo”, 34137 Trieste, Italy
3Department of Morphology, Surgery and Experimental Medicine and LTTA Centre, University of Ferrara, 44121 Ferrara, Italy
4Department of Life Sciences, University of Trieste, 34137 Trieste, Italy

Received 19 January 2015; Accepted 17 February 2015

Academic Editor: Maurizio Battaglia Parodi

Copyright © 2015 Paolo Perri et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. M. Pitti, S. A. Marsters, S. Ruppert, C. J. Donahue, A. Moore, and A. Ashkenazi, “Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family,” The Journal of Biological Chemistry, vol. 271, no. 22, pp. 12687–12690, 1996. View at Publisher · View at Google Scholar · View at Scopus
  2. S. R. Wiley, K. Schooley, P. J. Smolak et al., “Identification and characterization of a new member of the TNF family that induces apoptosis,” Immunity, vol. 3, no. 6, pp. 673–682, 1995. View at Publisher · View at Google Scholar · View at Scopus
  3. P. Secchiero and G. Zauli, “Tumor necrosis factor-related apoptosis-inducing ligand and the regulation of hematopoiesis,” Current Opinion in Hematology, vol. 15, no. 1, pp. 42–48, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. P. Secchiero, F. Corallini, A. Pandolfi et al., “An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction,” The American Journal of Pathology, vol. 169, no. 6, pp. 2236–2244, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Zauli, F. Corallini, F. Bossi et al., “Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo,” Blood, vol. 110, no. 2, pp. 536–543, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. K. W. Wagner, E. A. Punnoose, T. Januario et al., “Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL,” Nature Medicine, vol. 13, no. 9, pp. 1070–1077, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Mazurek, J. C. Byrd, Y. Sun et al., “Cell-surface galectin-3 confers resistance to TRAIL by impeding trafficking of death receptors in metastatic colon adenocarcinoma cells,” Cell Death and Differentiation, vol. 19, no. 3, pp. 523–533, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. E. Rimondi, P. Secchiero, A. Quaroni, C. Zerbinati, S. Capitani, and G. Zauli, “Involvement of TRAIL/TRAIL-receptors in human intestinal cell differentiation,” Journal of Cellular Physiology, vol. 206, no. 3, pp. 647–654, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. P. Secchiero, E. Melloni, F. Corallini et al., “Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells,” Stem Cells, vol. 26, no. 11, pp. 2955–2963, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. P. Secchiero, A. Gonelli, P. Mirandola et al., “Tumor necrosis factor-related apoptosis-inducing ligand induces monocytic maturation of leukemic and normal myeloid precursors through a caspase-dependent pathway,” Blood, vol. 100, no. 7, pp. 2421–2429, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. D. Campioni, P. Secchiero, F. Corallini et al., “Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes,” The American Journal of Pathology, vol. 166, no. 2, pp. 557–563, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. P. Secchiero, E. Rimondi, M. G. di Iasio et al., “C-reactive protein downregulates TRAIL expression in human peripheral monocytes via an Egr-1-dependent pathway,” Clinical Cancer Research, vol. 19, no. 8, pp. 1949–1959, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Zauli, E. Rimondi, V. Nicolin, E. Melloni, C. Celeghini, and P. Secchiero, “TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF,” Blood, vol. 104, no. 7, pp. 2044–2050, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. G. Zauli, E. Rimondi, S. Stea et al., “TRAIL inhibits osteoclastic differentiation by counteracting RANKL-dependent p27Kip1 accumulation in pre-osteoclast precursors,” Journal of Cellular Physiology, vol. 214, no. 1, pp. 117–125, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. G. Zauli, S. Sancilio, A. Cataldi, N. Sabatini, D. Bosco, and R. di Pietro, “PI-3K/Akt and NF-kappaB/IkappaBalpha pathways are activated in Jurkat T cells in response to TRAIL treatment,” Journal of Cellular Physiology, vol. 202, no. 3, pp. 900–911, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. R. di Pietro and G. Zauli, “Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L,” Journal of Cellular Physiology, vol. 201, no. 3, pp. 331–340, 2004. View at Publisher · View at Google Scholar
  17. N. Rathore, H. Matta, and P. M. Chaudhary, “An evolutionary conserved pathway of nuclear factor-κB activation involving caspase-mediated cleavage and N-end rule pathway-mediated degradation of IκBα,” The Journal of Biological Chemistry, vol. 279, no. 38, pp. 39358–39365, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. M. A. Degli-Esposti, W. C. Dougall, P. J. Smolak, J. Y. Waugh, C. A. Smith, and R. G. Goodwin, “The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain,” Immunity, vol. 7, no. 6, pp. 813–820, 1997. View at Publisher · View at Google Scholar · View at Scopus
  19. D. Milani, G. Zauli, E. Rimondi et al., “Tumour necrosis factor-related apoptosis-inducing ligand sequentially activates pro-survival and pro-apoptotic pathways in SK-N-MC neuronal cells,” Journal of Neurochemistry, vol. 86, no. 1, pp. 126–135, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. P. Secchiero, M. G. di Iasio, A. Gonelli, and G. Zauli, “The MDM2 inhibitor Nutlins as an innovative therapeutic tool for the treatment of haematological malignancies,” Current Pharmaceutical Design, vol. 14, no. 21, pp. 2100–2110, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. P. Secchiero, R. Bosco, C. Celeghini, and G. Zauli, “Recent advances in the therapeutic perspectives of nutlin-3,” Current Pharmaceutical Design, vol. 17, no. 6, pp. 569–577, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. P. Secchiero, C. Zerbinati, M. Grazia di Iasio et al., “Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells,” Current Drug Metabolism, vol. 8, no. 4, pp. 395–403, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. G. Zauli and P. Secchiero, “The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology,” Cytokine and Growth Factor Reviews, vol. 17, no. 4, pp. 245–257, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Ständer and T. Schwarz, “Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is expressed in normal skin and cutaneous inflammatory diseases, but not in chronically UV-exposed skin and non-melanoma skin cancer,” The American Journal of Dermatopathology, vol. 27, no. 2, pp. 116–121, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. L. Eidsmo, C. Fluur, B. Rethi et al., “FasL and TRAIL induce epidermal apoptosis and skin ulceration upon exposure to Leishmania major,” The American Journal of Pathology, vol. 170, no. 1, pp. 227–239, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. N. Vigneswaran, D. C. Baucum, J. Wu et al., “Repression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but not its receptors during oral cancer progression,” BMC Cancer, vol. 7, article 108, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. H.-O. Lee, J. M. Herndon, R. Barreiro, T. S. Griffith, and T. A. Ferguson, “TRAIL: a mechanism of tumor surveillance in an immune privileged site,” The Journal of Immunology, vol. 169, no. 9, pp. 4739–4744, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. P. Secchiero, G. Lamberti, F. Corallini et al., “Conjunctival sac fluid contains elevated levels of soluble TRAIL: implications for the anti-tumoral surveillance of the anterior surface of the eye,” Journal of Cellular Physiology, vol. 218, no. 1, pp. 199–204, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. P. Secchiero, P. Perri, E. Melloni et al., “Decreased levels of soluble TNF-related apoptosis-inducing ligand (TRAIL) in the conjunctival sac fluid of patients with diabetes affected by proliferative retinopathy,” Diabetic Medicine, vol. 28, no. 10, pp. 1277–1278, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. T. F. Babar, M. N. Khan, M. Hussain, S. A. Shah, M. Y. Khan, and M. D. Khan, “Spectrum of ocular surface squamous neoplasia,” Journal of the College of Physicians and Surgeons Pakistan, vol. 17, no. 6, pp. 344–346, 2007. View at Google Scholar · View at Scopus
  31. Y. S. Xu, J. X. Wang, and D. S. Yang, “Effects of human rhabdomyosarcoma cells by combining TRAIL with cisplatin,” Chinese Journal of Pediatric Surgery, vol. 27, no. 12, pp. 650–653, 2006. View at Google Scholar
  32. R. Komdeur, C. Meijer, M. van Zweeden et al., “Doxorubicin potentiates TRAIL cytotoxicity and apoptosis and can overcome TRAIL-resistance in RMS cells,” International Journal of Oncology, vol. 25, no. 3, pp. 677–684, 2004. View at Google Scholar · View at Scopus
  33. K. Klüttermann, U. Banning, M. Kachel, C. Krause, D. Körholz, and C. Mauz-Körholz, “TRAIL-induced cytotoxicity in a melphalan-resistant rhabdomyosarcoma cell line via activation of caspase-2,” Anticancer Research, vol. 26, no. 1, pp. 351–356, 2006. View at Google Scholar · View at Scopus
  34. S. Bakalian, J.-C. Marshall, P. Logan et al., “Molecular pathways mediating liver metastasis in patients with uveal melanoma,” Clinical Cancer Research, vol. 14, no. 4, pp. 951–956, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. Y. Zhou, X. Song, R. Jia et al., “Radiation-inducible human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene therapy: a novel treatment for radioresistant uveal melanoma,” Pigment Cell and Melanoma Research, vol. 23, no. 5, pp. 661–674, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. D. H. Ren, E. Mayhew, C. Hay, H. Li, H. Alizadeh, and J. Y. Niederkorn, “Uveal melanoma expression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptors and susceptibility to TRAIL-induced apoptosis,” Investigative Ophthalmology and Visual Science, vol. 45, no. 4, pp. 1162–1168, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. E. C. Borden, B. Jacobs, E. Hollovary et al., “Gene regulatory and clinical effects of interferon β in patients with metastatic melanoma: a phase II trial,” Journal of Interferon & Cytokine Research, vol. 31, no. 5, pp. 433–440, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Liu, L. Ma, C. Li, Z. Zhang, G. Yang, and W. Zhang, “Tumor-targeting TRAIL expression mediated by miRNA response elements suppressed growth of uveal melanoma cells,” Molecular Oncology, vol. 7, no. 6, pp. 1043–1055, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Venza, M. Visalli, T. Catalano et al., “Impact of DNA methyltransferases on the epigenetic regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in malignant melanoma,” Biochemical and Biophysical Research Communications, vol. 441, no. 4, pp. 743–750, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. I. Venza, M. Visalli, R. Oteri, D. Teti, and M. Venza, “Class I-specific histone deacetylase inhibitor MS-275 overrides TRAIL-resistance in melanoma cells by downregulating c-FLIP,” International Immunopharmacology, vol. 21, no. 2, pp. 439–446, 2014. View at Publisher · View at Google Scholar
  41. H. Liu, C. C. Jiang, C. J. Lavis et al., “2-Deoxy-D-glucose enhances TRAIL-induced apoptosis in human melanoma cells through XBP-1-mediated up-regulation of TRAIL-R2,” Molecular Cancer, vol. 8, article 122, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. J.-Z. Qin, H. Xin, and B. J. Nickoloff, “2-Deoxyglucose sensitizes melanoma cells to TRAIL-induced apoptosis which is reduced by mannose,” Biochemical and Biophysical Research Communications, vol. 401, no. 2, pp. 293–299, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. J.-Z. Qin, H. Xin, and B. J. Nickoloff, “Targeting glutamine metabolism sensitizes melanoma cells to TRAIL-induced death,” Biochemical and Biophysical Research Communications, vol. 398, no. 1, pp. 146–152, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. T. B. Karasic, T. K. Hei, and V. N. Ivanov, “Disruption of IGF-1R signaling increases TRAIL-induced apoptosis: a new potential therapy for the treatment of melanoma,” Experimental Cell Research, vol. 316, no. 12, pp. 1994–2007, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. J. A. Ferry, C. Y. Fung, L. Zukerberg et al., “Lymphoma of the ocular adnexa: a study of 353 cases,” The American Journal of Surgical Pathology, vol. 31, no. 2, pp. 170–184, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. E. H. J. Wissink, I. Verbrugge, S. R. Vink et al., “TRAIL enhances efficacy of radiotherapy in a p53 mutant, Bcl-2 overexpressing lymphoid malignancy,” Radiotherapy & Oncology, vol. 80, no. 2, pp. 214–222, 2006. View at Publisher · View at Google Scholar · View at Scopus
  47. J. Unnithan and R. M. Macklis, “TRAIL induction by radiation in lymphoma patients,” Cancer Investigation, vol. 22, no. 4, pp. 522–525, 2004. View at Publisher · View at Google Scholar · View at Scopus
  48. N. Finnberg, A. J. P. Klein-Szanto, and W. S. El-Deiry, “TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis,” The Journal of Clinical Investigation, vol. 118, no. 1, pp. 111–123, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. R. Di Pietro, P. Secchiero, R. Rana et al., “Ionizing radiation sensitizes erythroleukemic cells but not normal erythroblasts to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by selective up-regulation of TRAIL-R1,” Blood, vol. 97, no. 9, pp. 2596–2603, 2001. View at Publisher · View at Google Scholar · View at Scopus
  50. J. C. Lee, W. H. Lee, Y. J. Min et al., “Development of TRAIL resistance by radiation-induced hypermethylation of DR4 CpG Island in recurrent laryngeal squamous cell carcinoma,” International Journal of Radiation Oncology Biology Physics, vol. 88, no. 5, pp. 1203–1211, 2014. View at Publisher · View at Google Scholar · View at Scopus
  51. M. F. Silva, A. R. Khokhar, M. Z. Qureshi, and A. A. Farooqi, “Ionizing radiations induce apoptosis in TRAIL resistant cancer cells: in vivo and in vitro analysis,” Asian Pacific Journal of Cancer Prevention, vol. 15, no. 5, pp. 1905–1907, 2014. View at Publisher · View at Google Scholar · View at Scopus
  52. G. Zauli, B. Toffoli, M. G. di Iasio, C. Celeghini, B. Fabris, and P. Secchiero, “Treatment with recombinant tumor necrosis factor-related apoptosis-inducing ligand alleviates the severity of streptozotocin-induced diabetes,” Diabetes, vol. 59, no. 5, pp. 1261–1265, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. S. Bernardi, G. Zauli, C. Tikellis et al., “TNF-related apoptosis-inducing ligand significantly attenuates metabolic abnormalities in high-fat-fed mice reducing adiposity and systemic inflammation,” Clinical Science, vol. 123, no. 9, pp. 547–555, 2012. View at Publisher · View at Google Scholar · View at Scopus
  54. S. Bernardi, A. Norcio, B. Toffoli, G. Zauli, and P. Secchiero, “Potential role of TRAIL in the management of autoimmune diabetes mellitus,” Current Pharmaceutical Design, vol. 18, no. 35, pp. 5759–5765, 2012. View at Publisher · View at Google Scholar · View at Scopus
  55. J. Threatt, J. F. Williamson, K. Huynh, and R. M. Davis, “Ocular disease, knowledge and technology applications in patients with diabetes,” The American Journal of the Medical Sciences, vol. 345, no. 4, pp. 266–270, 2013. View at Publisher · View at Google Scholar · View at Scopus
  56. T.-C. Ho, S.-L. Chen, S.-C. Shih et al., “Pigment epithelium-derived factor (PEDF) promotes tumor cell death by inducing macrophage membrane tumor necrosis factor-related apoptosis-inducing ligand (TRAIL),” The Journal of Biological Chemistry, vol. 286, no. 41, pp. 35943–35954, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. K. E. Hubert, M. H. Davies, A. J. Stempel, T. S. Griffith, and M. R. Powers, “TRAIL-deficient mice exhibit delayed regression of retinal neovascularization,” The American Journal of Pathology, vol. 175, no. 6, pp. 2697–2708, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. P. Secchiero, F. Corallini, M. G. Di Iasio, A. Gonelli, E. Barbarotto, and G. Zauli, “TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release,” Blood, vol. 105, no. 9, pp. 3413–3419, 2005. View at Publisher · View at Google Scholar · View at Scopus
  59. P. Secchiero, R. Candido, F. Corallini et al., “Systemic TRAIL delivery shows anti atherosclerotic activity in ApoE-nulldiabetic mice,” Circulation, vol. 114, no. 14, pp. 1522–1530, 2006. View at Google Scholar
  60. A. Flyvbjerg, “Diabetic angiopathy, the complement system and the tumor necrosis factor superfamily,” Nature Reviews Endocrinology, vol. 6, no. 2, pp. 94–101, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. P. Secchiero, F. Corallini, C. Ceconi et al., “Potential prognostic significance of decreased serum levels of TRAIL after acute myocardial infarction,” PLoS ONE, vol. 4, no. 2, Article ID e4442, 2009. View at Publisher · View at Google Scholar · View at Scopus
  62. P. Secchiero, F. Corallini, A. P. Beltrami et al., “An imbalanced OPG/TRAIL ratio is associated to severe acute myocardial infarction,” Atherosclerosis, vol. 210, no. 1, pp. 274–277, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. S. Volpato, L. Ferrucci, P. Secchiero et al., “Association of tumor necrosis factor-related apoptosis-inducing ligand with total and cardiovascular mortality in older adults,” Atherosclerosis, vol. 215, no. 2, pp. 452–458, 2011. View at Publisher · View at Google Scholar · View at Scopus
  64. W. Cheng, Y. Zhao, S. Wang, and F. Jiang, “Tumor necrosis factor-related apoptosis-inducing ligand in vascular inflammation and atherosclerosis: a protector or culprit?” Vascular Pharmacology, vol. 63, no. 3, pp. 135–144, 2014. View at Publisher · View at Google Scholar
  65. A. Kargi, A. D. Yalcin, N. Erin, B. Savas, H. H. Polat, and R. M. Gorczynski, “IL8 and serum soluble TRAIL levels following anti-VEGF monoclonal antibody treatment in patients with metastatic colon cancer,” Clinical Laboratory, vol. 58, no. 5-6, pp. 501–505, 2012. View at Google Scholar · View at Scopus
  66. A. Bisgin, A. Kargi, A. D. Yalcin et al., “Increased serum sTRAIL levels were correlated with survival in bevacizumab-treated metastatic colon cancer,” BMC Cancer, vol. 12, article 58, 2012. View at Publisher · View at Google Scholar · View at Scopus
  67. P.-L. Chen and A. S. Easton, “Evidence that tumor necrosis factor-related apoptosis inducing ligand (TRAIL) inhibits angiogenesis by inducing vascular endothelial cell apoptosis,” Biochemical and Biophysical Research Communications, vol. 391, no. 1, pp. 936–941, 2010. View at Publisher · View at Google Scholar · View at Scopus
  68. G. Cantarella, N. Risuglia, R. Dell'Eva et al., “TRAIL inhibits angiogenesis stimulated by VEGF expression in human glioblastoma cells,” British Journal of Cancer, vol. 94, no. 10, pp. 1428–1435, 2006. View at Publisher · View at Google Scholar · View at Scopus
  69. Y. Sun, S. Li, H. Li et al., “TNFRSF10A-LOC389641 rs13278062 but not REST-C4orf14-POLR2B-IGFBP7 rs1713985 was found associated with age-related macular degeneration in a Chinese population,” Investigative Ophthalmology & Visual Science, vol. 54, no. 13, pp. 8199–8203, 2013. View at Publisher · View at Google Scholar · View at Scopus
  70. A. Anand, N. K. Sharma, R. Singh et al., “Does DcR1 (TNF-related apoptosis-inducing-ligand Receptor 3) have any role in human AMD pathogenesis?” Scientific Reports, vol. 4, article 4114, 2014. View at Publisher · View at Google Scholar · View at Scopus
  71. J. L. Dunaief, T. Dentchev, G.-S. Ying, and A. H. Milam, “The role of apoptosis in age-related macular degeneration,” Archives of Ophthalmology, vol. 120, no. 11, pp. 1435–1442, 2002. View at Publisher · View at Google Scholar · View at Scopus